Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628924 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT03628924 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 184 participants.
The verdict
NCT03628924, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
Interventions
- DRUG Placebo
- DRUG Guselkumab dose 1
- DRUG Guselkumab dose 2
- DRUG Guselkumab dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2020-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03628924
The ClinicalTrials.gov registry entry for NCT03628924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03628924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03628924 about?
NCT03628924 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)". The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
What is the current status of trial NCT03628924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2018-09-04. Estimated completion is 2020-05-22.
What interventions are being tested in trial NCT03628924?
The interventions under investigation include: Placebo (DRUG), Guselkumab dose 1 (DRUG), Guselkumab dose 2 (DRUG), Guselkumab dose 3 (DRUG).
Who is sponsoring clinical trial NCT03628924?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.